Actue meyloid leukemia
Conditions
Interventions
Trial group:homoharringtonine plus venetoclax
Sponsors
Nanfang Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with newly diagnosed unfit acute myeloid leukemia and aged >= 18 years; 2. Sign informed consent form, have the ability to comply with study and follow-up procedures.
Exclusion criteria
Exclusion criteria: 1. Acute promyelocytic leukemia (AML subtype M3); 2. Life expectancy less than 30 days after the therapy; 3. Cardiac dysfunction ( particularly congestive heart failure, unstable coronary artery disease and serious cardiac ventricular arrhythmias requiring antiarrhythmic therapy); 4. Respiratory failure; 5. Hepatic abnormalities, total bilirubin >= 3 times the upper limit of normal (ULN), alanine aminotransferase or aspartate aminotransferase >= 5 times the ULN; 6. Renal dysfunction; Cr < 30 mL/min; 7. Cobination with secondary tumor; 8. Being allergic to the clinical drugs; 9. Patients with pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Event-free survival;Overall survival;Relapse;Composite complete remission;Minimal residual disease; | — |
Countries
China
Contacts
Public ContactGuopan Yu
Nanfang Hospital of Southern Medical University
Outcome results
None listed